Education
About Us
Working with TipRanks
Follow Us
Oruka Therapeutics (ORKA)
NASDAQ:ORKA
Total Valuation
Oruka Therapeutics has a market cap or net worth of $1.98B. The enterprise value is $1.45B.
Market Cap$1.98B
Enterprise Value$1.45B
Share Statistics
Oruka Therapeutics has 49,542,690 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding49,542,690
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Oruka Therapeutics’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -25.76%.
Return on Equity (ROE)-0.22
Return on Assets (ROA)-0.22
Return on Invested Capital (ROIC)-25.76%
Return on Capital Employed (ROCE)-0.26
Revenue Per Employee0.00
Profits Per Employee-3.77M
Employee Count28
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Oruka Therapeutics is ―. Oruka Therapeutics’s PEG ratio is 0.24.
PE Ratio―
PS Ratio0.00
PB Ratio2.93
Price to Fair Value2.93
Price to FCF-15.64
Price to Operating Cash Flow-24.68
PEG Ratio0.24
Income Statement
In the last 12 months, Oruka Therapeutics had revenue of 0.00 and earned -105.43M in profits. Earnings per share was -2.31.
Revenue0.00
Gross Profit-83.00K
Operating Income-122.05M
Pretax Income-105.43M
Net Income-105.43M
EBITDA-121.97M
Earnings Per Share (EPS)-2.31
Cash Flow
In the last 12 months, operating cash flow was -88.21M and capital expenditures -209.00K, giving a free cash flow of -88.42M billion.
Operating Cash Flow-88.21M
Free Cash Flow-88.42M
Free Cash Flow per Share-1.78
Dividends & Yields
Oruka Therapeutics pays an annual dividend of $19.356, resulting in a dividend yield of ―
Dividend Per Share$19.356
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.76
52-Week Price Change236.42%
50-Day Moving Average32.78
200-Day Moving Average23.07
Relative Strength Index (RSI)67.12
Average Volume (3m)530.53K
Important Dates
Oruka Therapeutics upcoming earnings date is May 20, 2026, TBA (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateMay 20, 2026
Ex-Dividend Date―
Financial Position
Oruka Therapeutics as a current ratio of 22.37, with Debt / Equity ratio of 0.41%
Current Ratio22.37
Quick Ratio22.37
Debt to Market Cap<0.01
Net Debt to EBITDA0.37
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Oruka Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Oruka Therapeutics EV to EBITDA ratio is -10.97, with an EV/FCF ratio of -15.13.
EV to Sales0.00
EV to EBITDA-10.97
EV to Free Cash Flow-15.13
EV to Operating Cash Flow-15.16
Balance Sheet
Oruka Therapeutics has $337.04M in cash and marketable securities with $1.93M in debt, giving a net cash position of $335.11M billion.
Cash & Marketable Securities$337.04M
Total Debt$1.93M
Net Cash$335.11M
Net Cash Per Share$6.76
Tangible Book Value Per Share$10.35
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Oruka Therapeutics is $61.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$61.50
Price Target Upside53.75% Upside
Analyst ConsensusStrong Buy
Analyst Count13
Revenue Growth Forecast―
EPS Growth Forecast63.85%